ORYZON GENOMICS, S.A. «...678910...» Page 8 out of 13 16/09/2022 07:52 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder at the European Conference on Mental Health Register number: 18274 01/09/2022 13:40 ORYZON GENOMICS, S.A. Total number of voting rights and capital Ampliación de Capital por conversión de obligaciones Register number: 18100 22/07/2022 07:05 ORYZON GENOMICS, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2022 Register number: 17481 19/07/2022 08:00 ORYZON GENOMICS, S.A. Other relevant information ORYZON announces Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) to develop iadademstat in different cancers Register number: 17424 05/07/2022 07:23 ORYZON GENOMICS, S.A. Other relevant information The Company has subscribed an investment agreement for a total amount of up to 20 million euros Register number: 17199 04/07/2022 12:43 ORYZON GENOMICS, S.A. Announcement of general shareholders’ meeting Oryzon Genomics, S.A. informs about the resolutions passed by the Ordinary General Shareholders’ Meeting Register number: 17186 10/06/2022 07:51 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents new positive efficacy data of iadademstat from the ongoing Phase IIa ALICE clinical trial in acute myeloid leukemia at the EHA-2022 congress. Register number: 16735 08/06/2022 07:58 ORYZON GENOMICS, S.A. Other relevant information ORYZON granted Orphan Drug Designation by FDA for iadademstat for the treatment of small cell lung cancer. Register number: 16658 23/05/2022 12:53 ORYZON GENOMICS, S.A. Announcement of general shareholders’ meeting Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A. Register number: 16395 05/05/2022 18:04 ORYZON GENOMICS, S.A. Other relevant information La Sociedad remite información sobre los resultados del primer trimestre del año 2022 Register number: 16064 Page 8 out of 13 «...678910...»
